Anti-DCBLD2/ESDN Antibody (FA19-1) is a humanized monoclonal antibody targeting Discoidin, CUB and LCCL domain-containing protein 2 (DCBLD2/ESDN/CLCP1). DCBLD2 is a type I transmembrane protein overexpressed in various malignancies (e.g., lung adenocarcinoma, glioma) and acts as a signal relay for growth factor signaling like EGFR. FA19-1 specifically binds to the extracellular domain of DCBLD2, blocking its mediated signaling—such as AKT activation or cisplatin-induced EMT—thereby inhibiting tumor cell migration, invasion, and distant metastasis.